Overview

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

Status:
Completed

Trial end date:
2018-04-20

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.

Phase:

Phase 3

Details

Lead Sponsor:

Shionogi

Treatments:

Baloxavir
Oseltamivir